Neovacs SA ALNEV.PA
Last Updated: Jul 17, 12:00 AM·XPAR
ALNEV.PA Shariah Compliance
Screening Methodology: AAOIFI
As of July 2026, Neovacs SA is classified as not halal.
NOT HALAL
Report Source: 2024 Annual Report
Neovacs SA. Stock Analysis ALNEV.PA
France Health Care Nano Cap Report: Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The company is headquartered in Suresnes, Ile-De-France and currently employs 16 full-time employees. The company went IPO on 2010-04-15. The company specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The firm researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The firm focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The firm operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
Read More Neovacs SA (ALNEV.PA) Chart
Key Statistics of Neovacs SA (ALNEV.PA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
€0.99Volume
9746.00P/E Ratio (TTM)
-52 Week Range
Market Cap
201.85KAvg. Volume
3.97MDividend Yield
-Financial Metrics & Statements of Neovacs SA (ALNEV.PA)
Super Investors Invested in Neovacs SA (ALNEV.PA)
FAQ's for Neovacs SA (ALNEV.PA)
- As of July 2026, Neovacs SA ALNEV.PA is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Neovacs SA using these criteria to determine its compliance status.
- Muslim investors may consider investing in Neovacs SA if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Neovacs SA by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Neovacs SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Neovacs SA on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.